Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...